Cellular Health Screening Market Valued at US$ 2.6 Billion Poised to Witness a Healthy Growth rate of 9% in the coming 5 years
Rising government initiatives towards preventive
healthcare, rapid growth in geriatric population, increased funding & investments
in R&D activities, growing adoption of direct-to-consumer approach,
increasing applications of cellular health screening in personalized medicine,
and huge burden of chronic diseases are some of the key factors driving the
cellular health screening market.
Cellular
health screening or testing is one of the determinants of health based on
certain factors such as lifestyle, environment, emotions and diet. It can be
used to evaluate inflammatory diseases such allergies, asthma, arthritis,
autoimmune diseases, or inflammatory gastrointestinal issues. This test also aids
in monitoring a patient’s progress throughout the treatment and provide
detailed reports to examine and assess improvements on a cellular level.
Cellular health screening helps in determining cellular health & function,
fat mass, intra & extracellular fluid levels, cellular toxicity, and muscle
mass, among others.
Advancements in cellular health screening
to fuel the demand in the Cellular Health Screening Market
The
ongoing progress in screening tests for cellular health has facilitated the
creation of user-friendly and effective tests that come with enhanced
capabilities like automated identification of telomeres, rapid results, and
heightened precision. Such advancements tend to provide competitive edge to
manufacturers and therefore, major players are continuously focusing on new
product development to strengthen their foothold in this high growth market.
Some of the technological advancements are listed below:
·
In December 2022, Regenerus labs launched its TruAge Complete, an advanced
epigenetic test that provide an accurate, comprehensive, and actionable
analysis of a patient’s biological ageing and health insights
·
In August 2022, Proteomics International
Laboratories announced the
spin-off of an independent business for the commercialization of its patented
‘2-tag’ technology developed together with The University of Western Australia
· In July 2022, Bloom Diagnostics, a Swiss med-tech company launched its Bloom Inflammation Test to test for the quantitative measurement and presence of C-Reactive Protein (CRP) using the Bloom system
Increasing research activities to drive
innovation in cellular health screening market
Growth in the cellular health screening market is expected to be fueled
by the Growing public awareness campaigns aimed at educating individuals about
the symptoms of chronic diseases and how to prevent them in order minimise
disease epidemics. Because of increased patient awareness and high demand,
there is a substantial need for novel cellular health screening kits and
services which has compelled researchers to focus on innovation and develop
advanced diagnostic tests. Some of these are listed below-
·
In February 2023,
Duke-NUS Medical School announced that Scientists at the Duke-NUS Medical
School, National Heart Centre Singapore (NHCS) and colleagues in Singapore,
China and the US have developed a test to quickly and precisely measure the
length of a single telomere. The new approach is expected to be used as a
predictive biomarker for human ageing and disease at the individual level
·
In March 2021,
Researchers at Queen Mary University of London and Cardiff University developed
a rapid laboratory test for diagnosing patients exhibiting symptoms arising
from telomeropathies. This high-throughput single telomere length analysis
(HT-STELA) technique is a DNA-based blood test and can be applied to a broader
range of samples including fresh or frozen blood samples
The cellular health screening market is a burgeoning industry that is
poised to gather additional momentum in the near future. This can be attributed
to the strong emphasis on innovation, greater acceptance and awareness of
preventive healthcare, the rapid growth of the aging population, and increased
efforts by market players to expand their geographic presence, among other factors.
For instance, by 2030, 1 in 6 people in the world will be aged 60 years or
over. At this time, the share of the population aged 60 years and over will expand
from 1 billion in 2020 to 1.4 billion. Aging increases the risk of chronic
diseases and infections which further demands preventive diagnostic tests,
thereby driving the cellular health screening market growth.
Competitive landscape: Cellular Health Screening Market
The market is marked by the presence of key players such Quest Diagnostics (US); Telomere Diagnostics (US); SpectraCell Laboratories (US); Genova Diagnostics (US); LabCorp Holdings (US); Repeat Diagnostics, Inc. (Canada); Life Length (Spain); and others.
Get Detailed Insights on the Cellular Health
Screening Market @ https://meditechinsights.com/cellular-health-screening-market/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech
Insights
Comments
Post a Comment